The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.
Cebranopadol reduced pain intensity in patients following abdominoplasty surgery in the ALLEVIATE-1 clinical trial.
Mood lability due to oral contraceptive use was associated with a higher likelihood of oral contraceptive discontinuation in endometriosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback